A Phase 2 interventional study of Durvalumab and Tremelimumab and AZD1775 and carboplatin (CBPT) in Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma, sponsored by AstraZeneca. Completed at 12 sites in 5 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-06-07.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing carboplatin in Small Cell Lung Carcinoma — 6 open to participants now, 9 under way, 1 of them phase 3. Carboplatin · Small Cell Lung Carcinoma.
Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, this one is the 9th largest by enrollment, is the only one that started in 2016, is one of 22 in phase 2, and was the 16th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →6 of the 36 studies testing carboplatin in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 39 more countries
Ages 18+
Sehhoon Park · Sites in Korea, Republic of
Ages 19+
Anhui Provincial Cancer Hospital · Sites in China
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 26 · Phase 3 4
First in 1998; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 48 across the 36 interventional studies. Of the 22 that completed or were terminated, 10 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 36 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
25 studies in Small Cell Lung Carcinoma by AstraZeneca: 3 open now, 10 under way, 3 of them phase 3. Of 15 finished, 4 (27%) have results posted.
Among the 25 studies in Small Cell Lung Carcinoma by AstraZeneca, this one is the 10th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2016, is one of 3 in phase 2, and was the 7th registered.
AstraZeneca’s Small Cell Lung Carcinoma studies by the year they started, since 2004.
4 of the studies testing carboplatin in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05856695Intergroupe Francophone de Cancerologie ThoraciqueDurvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) | 2026-11 |
| NCT06838208Anhui Provincial Cancer HospitalTislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | 2027-03-01 |
| NCT06830694Sehhoon ParkClinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment | 2027-03-31 |
| NCT06449209BioNTech SESafety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 36 studies testing carboplatin in Small Cell Lung Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 25 in Small Cell Lung Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study design This is a Phase II, open-label, multi-drug, multi-center, multi-arm, signal-searching study in patients with extensive-stage small-cell lung cancer (SCLC) who have refractory or resistant disease from prior platinum-based chemotherapy.
This study is modular in design, allowing evaluation of the preliminary efficacy, safety, tolerability, and immunogenicity of novel combinations of immunotherapies and/or deoxyribonucleic acid (DNA) damage repair inhibitors in patients with platinum refractory or resistant extensive-stage-disease SCLC. Patients who have progressive disease (PD) during first-line platinum-based chemotherapy (platinum refractory) or PD within 90 days after completing first-line platinum-based chemotherapy (platinum resistant) will be enrolled to the study. The primary objective of the study is to assess the preliminary efficacy of each treatment arm based on objective response rate (ORR).
This study consists of a number of arms (sub-studies), each evaluating the efficacy, safety, and tolerability of a specific agent or combination. This study was initially open with 2 arms (Arms A and B), and additional arms may open, provided there is compelling rationale for the combination and safe and tolerable doses and schedules have been determined from ongoing Phase I studies. There are 2 pre-defined arms:
A. Durvalumab + tremelimumab followed by durvalumab monotherapy B. AZD1775 + carboplatin (CBDP)
Further arm was added in amendment 3:
C. AZD6738 + olaparib Amendment #4 was updated with possibility to allow expansion of any arm, to a total of 40 eligible subjects, based on Review Committee assessment of data from the first 20 subjects (from Stage 1 and Stage 2). Currently Arm A will enroll 20 additional patients into expansion.
Inclusion criteria (applicable to all arms)
Inclusion criteria (Arm A specific)
Inclusion criteria (Arm B specific) • Able and willing to swallow oral medication.
Inclusion criteria (Arm C specific)
Exclusion criteria (applicable to all arms):
Exclusion criteria (Arm A specific)
Exclusion criteria (Arm B specific)
Exclusion criteria (Arm C specific)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Durvalumab and Tremelimumab
Drug: AZD1775 and carboplatin (CBPT)
Drug: AZD6738 and olaparib
Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
Drug pages: Adavosertib · Carboplatin
AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
Drug pages: Ceralasertib · Olaparib
AZD6738 once a day (oral) for 7 days from Day 1 + olaparib twice a day(oral) for 28 days from Day 1, every 4 weeks
This study also gives Durvalumab, Tremelimumab. No intervention listed here names it: that was found by reading the record.
Number of Participants With Overall Response
Overall Response Rate (ORR) using Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. ORR was defined as the number (percentage) of participants with a confirmed Complete Response (CR) or confirmed Partial Response (PR) and was estimated for each treatment arm with corresponding 2-sided 95% exact confidence intervals (CIs). A confirmed response of CR/PR meant that a response of CR/PR was recorded at one visit and confirmed by repeat imaging, preferably at the next regularly scheduled imaging visit, and not less than 4 weeks after the visit when the response was first observed, with no evidence of progression between the initial and CR/PR confirmation visit.
Time frame: Until disease progression [PD] (Up to 3.5 Years)
Duration of Response (DoR)
The DoR was defined as the time from the date of first documented response (which was subsequently confirmed) CR/PR until the date of documented progression, or death in the absence of disease progression. The DoR in participants with confirmed objective response are reported.
Time frame: Until disease progression or data cut-off or Death (Up to 3.5 Years)
Percentage of Participants With Disease Control at 12 Weeks
The disease control rate (DCR) at 12 weeks was defined as the percentage of participants who had a best objective response of CR or PR in the first 13 weeks or who had demonstrated stable disease (SD) for a minimum interval of 11 weeks following the start of study treatment. The DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event.
Time frame: At 12 Weeks
Time to Response (TTR)
The TTR (per RECIST 1.1 as assessed by the Investigator) was defined as the time from the date of first dose until the first date of documented response.
Time frame: Until disease progression or data cut-off or Death (Up to 3.5 Years)
Progression Free Survival (PFS)
The PFS (per RECIST 1.1 according to the Investigator's assessment) was defined as the time from the date of the first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from allocated therapy or received another anti-cancer therapy prior to progression.
Time frame: Until disease progression or data cut-off or Death (Up to 3.5 Years)
Overall Survival (OS)
The OS was defined as the time from the date of the first dose of study treatment until death due to any cause.
Time frame: Until disease progression or data cut-off or Death (Up to 3.5 Years)
Time to Maximum Concentration (Tmax)
Time to maximum concentration for ceralasertib and olaparib are reported.
Time frame: Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose)
Maximum Concentration (Cmax)
Maximum concentration for ceralasertib and olaparib are reported.
Time frame: Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose)
Partial Area Under the Concentration-time Curve (AUC0-6)
Partial area under the concentration-time curve for ceralasertib and olaparib are reported.
Time frame: Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose) and Cycle 1 Day 7 (pre-dose and post-dose)
Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t)
Area under the concentration-time curve from time zero to the last measurable concentration for Ceralasertib and Olaparib are reported.
Time frame: Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose) and Cycle 1 Day 7 (pre-dose and post-dose)
Time to Maximum Concentration at Steady State (Tmax,ss)
Time to maximum concentration at steady state for Ceralasertib and Olaparib are reported.
Time frame: Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)
Maximum Concentration at Steady State (Cmax,ss)
Maximum concentration at steady state for Ceralasertib and Olaparib are reported.
Time frame: Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)
Minimum Concentration at Steady State (Cmin,ss)
Minimum concentration at steady state for Ceralasertib and Olaparib are reported.
Time frame: Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)
Area Under the Concentration-time Curve at Steady State (AUCss)
Area under the concentration-time curve at steady state at steady state for Ceralasertib and Olaparib are reported.
Time frame: Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)
Apparent Clearance of Drug at Steady State at Steady State (CLss/F)
Area under the concentration-time curve at steady state at steady state for Ceralasertib and Olaparib are reported.
Time frame: Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)
Serum Concentrations of Durvalumab and Tremelimumab
Serum concentrations of Durvalumab and Tremelimumab are reported.
Time frame: Durvalumab: Cycle 1 (each cycle was 4 weeks) Day 1(post-dose); Cycle 2 Day 1(pre-dose); Cycle 5 Day 1 (pre-dose); Tremelimumab: Cycle 1 (each cycle was 4 weeks) Day 1 (post-dose); Cycle 2 Day 1 (pre-dose); Cycle 5 Day 1 (No dose); Cycle 7 Day 1 (No dose)
Plasma Concentrations of Adavosertib and Carboplatin
Plasma concentrations of Adavosertib and Carboplatin are reported.
Time frame: Adavosertib: Cycle 1 (each cycle was 21 days) Day 3 (pre-dose and post-dose); Cycle 3 Day 3 (pre-dose and post-dose); Carboplatin: Cycle 1 (each cycle was 21 days) Day 1 (post-dose)
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.
Time frame: Day 1 until disease progression, and follow-up visit (Up to 3.5 Years)
The study was conducted between 28-Nov-2016 and 22-Jun-2020, at 11 study centers in 5 countries (Germany, Hungary, Poland, Spain, and Ukraine).
| Milestone | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib |
|---|---|---|---|---|
| Started | 21 | 20 | 10 | 21 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 21 | 20 | 10 | 21 |
| Withdrew: Participants decision | 2 | 1 | 1 | 1 |
| Withdrew: Adverse event | 2 | 4 | 1 | 1 |
| Withdrew: Disease progression | 17 | 15 | 7 | 19 |
| Withdrew: Condition under investigation worsened | 0 | 0 | 1 | 0 |
Overall Response Rate (ORR) using Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. ORR was defined as the number (percentage) of participants with a confirmed Complete Response (CR) or confirmed Partial Response (PR) and was estimated for each treatment arm with corresponding 2-sided 95% exact confidence intervals (CIs). A confirmed response of CR/PR meant that a response of CR/PR was recorded at one visit and confirmed by repeat imaging, preferably at the next regularly scheduled imaging visit, and not less than 4 weeks after the visit when the response was first observed, with no evidence of progression between the initial and CR/PR confirmation visit.
| Participants | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib |
|---|---|---|---|---|
| Number of Participants With Overall Response | 2 | 1 | 0 | 1 |
The DoR was defined as the time from the date of first documented response (which was subsequently confirmed) CR/PR until the date of documented progression, or death in the absence of disease progression. The DoR in participants with confirmed objective response are reported.
| Months | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib |
|---|---|---|---|---|
| Duration of Response (DoR) | NA (1.5 to NA) | 3 (3 to 3) | — | 8.5 (8.5 to 8.5) |
The disease control rate (DCR) at 12 weeks was defined as the percentage of participants who had a best objective response of CR or PR in the first 13 weeks or who had demonstrated stable disease (SD) for a minimum interval of 11 weeks following the start of study treatment. The DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event.
| Percentage of Participants | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib |
|---|---|---|---|---|
| Percentage of Participants With Disease Control at 12 Weeks | 38.1 | 15.0 | 30.0 | 38.1 |
The TTR (per RECIST 1.1 as assessed by the Investigator) was defined as the time from the date of first dose until the first date of documented response.
| Months | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib |
|---|---|---|---|---|
| Time to Response (TTR) | 1.8 (1.7 to 1.8) | 1.8 (1.8 to 1.8) | — | 1.7 (1.7 to 1.7) |
The PFS (per RECIST 1.1 according to the Investigator's assessment) was defined as the time from the date of the first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from allocated therapy or received another anti-cancer therapy prior to progression.
| Months | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 1.91 (1.77 to 4.34) | 1.77 (1.02 to 2.20) | 2.60 (0.56 to 4.83) | 2.92 (1.81 to 4.53) |
The OS was defined as the time from the date of the first dose of study treatment until death due to any cause.
| Months | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib |
|---|---|---|---|---|
| Overall Survival (OS) | 5.95 (1.91 to 10.61) | 3.37 (1.91 to 7.66) | 4.67 (0.56 to 5.98) | 7.56 (4.21 to 12.58) |
Time to maximum concentration for ceralasertib and olaparib are reported.
| Hour | Ceralasertib (AZD6738) | Olaparib |
|---|---|---|
| Time to Maximum Concentration (Tmax) | 1.250 (1.00 to 6.08) | 1.800 (1.00 to 6.08) |
Maximum concentration for ceralasertib and olaparib are reported.
| µg/mL | Ceralasertib (AZD6738) | Olaparib |
|---|---|---|
| Maximum Concentration (Cmax) | 4.215 ± 27.7129 | 6.558 ± 39.9411 |
Partial area under the concentration-time curve for ceralasertib and olaparib are reported.
| h*µg/mL | Ceralasertib (AZD6738) | Olaparib |
|---|---|---|
| Cycle 1, Day 1 | 18.346 ± 34.6952 | 26.356 ± 42.2963 |
| Cycle 1, Day 7 | 23.666 ± 23.9202 | 42.016 ± 33.7599 |
Area under the concentration-time curve from time zero to the last measurable concentration for Ceralasertib and Olaparib are reported.
| h*µg/mL | Ceralasertib (AZD6738) | Olaparib |
|---|---|---|
| Cycle 1, Day 1 | 18.575 ± 34.5074 | 26.973 ± 41.4461 |
| Cycle 1, Day 7 | 24.061 ± 23.0923 | 62.535 ± 42.4552 |
Time to maximum concentration at steady state for Ceralasertib and Olaparib are reported.
| Hour | Ceralasertib (AZD6738) | Olaparib |
|---|---|---|
| Time to Maximum Concentration at Steady State (Tmax,ss) | 1.875 (0.63 to 6.08) | 2.708 (0.63 to 4.50) |
Maximum concentration at steady state for Ceralasertib and Olaparib are reported.
| µg/mL | Ceralasertib (AZD6738) | Olaparib |
|---|---|---|
| Maximum Concentration at Steady State (Cmax,ss) | 5.176 ± 23.4058 | 9.189 ± 30.4888 |
Minimum concentration at steady state for Ceralasertib and Olaparib are reported.
| µg/mL | Ceralasertib (AZD6738) | Olaparib |
|---|---|---|
| Minimum Concentration at Steady State (Cmin,ss) | 1.119 ± 55.9070 | 2.376 ± 61.8191 |
Area under the concentration-time curve at steady state at steady state for Ceralasertib and Olaparib are reported.
| h*µg/mL | Ceralasertib (AZD6738) | Olaparib |
|---|---|---|
| Area Under the Concentration-time Curve at Steady State (AUCss) | NA ± NA | 67.929 ± 37.4297 |
Area under the concentration-time curve at steady state at steady state for Ceralasertib and Olaparib are reported.
| Litre/hour | Ceralasertib (AZD6738) | Olaparib |
|---|---|---|
| Apparent Clearance of Drug at Steady State at Steady State (CLss/F) | NA ± NA | 4.416 ± 42.3171 |
Serum concentrations of Durvalumab and Tremelimumab are reported.
| μg/mL | Arm A: Durvalumab + Tremelimumab (Original Cohort) |
|---|---|
| Durvalumab: Cycle 1 Day 1 (Post-dose) | 391.192 ± 23.5990 |
| Durvalumab: Cycle 2 Day 1 (Pre-dose) | 55.590 ± 53.0745 |
| Durvalumab: Cycle 5 Day 1 (Pre-dose) | 116.846 ± 51.0036 |
| Tremelimumab: Cycle 1 Day 1 (Post-dose) | 18.299 ± 20.8181 |
| Tremelimumab: Cycle 2 Day 1 (Pre-dose) | 2.650 ± 53.1007 |
| Tremelimumab: Cycle 5 Day 1 (No dose) | 5.005 ± 38.3784 |
| Tremelimumab: Cycle 7 Day 1 (No dose) | 0.784 ± 66.3469 |
Plasma concentrations of Adavosertib and Carboplatin are reported.
| nM | Arm B: Adavosertib + Carboplatin |
|---|---|
| Adavosertib: Cycle 1 Day 3 (Pre-dose) | 551.489 ± 41.5823 |
| Adavosertib: Cycle 1 Day 3 (Post-dose) | 728.342 ± 62.3968 |
| Adavosertib: Cycle 3 Day 3 (Pre-dose) | 606.571 ± 46.7716 |
| Adavosertib: Cycle 3 Day 3 (Post-dose) | 805.270 ± 68.0275 |
| Carboplatin: Cycle 1 Day 1 (Post-dose) | 12834.615 ± 27.5493 |
An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.
| Participants | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib |
|---|---|---|---|---|
| Any AE | 16 | 17 | 8 | 18 |
| Any AE causally related to any study treatment | 10 | 9 | 8 | 16 |
| Any AE with outcome = death | 1 | 0 | 1 | 1 |
| Any SAE | 6 | 8 | 4 | 7 |
| Any AE leading to discontinuation of any study treatment | 2 | 4 | 1 | 1 |
Collected over Day 1 until disease progression, and follow-up visit (Up to 3.5 Years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Durvalumab + Tremelimumab (Original Cohort) | 19/21 (90.5%) | 6/21 (28.6%) | 14/21 (66.7%) |
| Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | 16/20 (80%) | 8/20 (40%) | 16/20 (80%) |
| Arm B: Adavosertib + Carboplatin | 10/10 (100%) | 4/10 (40%) | 8/10 (80%) |
| Arm C: Ceralasertib (AZD6738) + Olaparib | 15/21 (71.4%) | 7/21 (33.3%) | 13/21 (61.9%) |
| Event | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/21 | 1/20 | 0/10 | 4/21 |
| DiarrhoeaGastrointestinal disorders | 2/21 | 1/20 | 1/10 | 0/21 |
| Toxicity to various agentsInjury, poisoning and procedural complications | 1/21 | 0/20 | 1/10 | 0/21 |
| HaematotoxicityBlood and lymphatic system disorders | 0/21 | 0/20 | 1/10 | 0/21 |
| PancytopeniaBlood and lymphatic system disorders | 0/21 | 0/20 | 1/10 | 0/21 |
| GastroenteritisInfections and infestations | 0/21 | 1/20 | 0/10 | 0/21 |
| PneumoniaInfections and infestations | 0/21 | 1/20 | 0/10 | 1/21 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/21 | 1/20 | 0/10 | 0/21 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/21 | 1/20 | 0/10 | 1/21 |
| HypokalaemiaMetabolism and nutrition disorders | 0/21 | 1/20 | 0/10 | 0/21 |
| Event | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/21 | 3/20 | 7/10 | 1/21 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/21 | 1/20 | 7/10 | 1/21 |
| NauseaGastrointestinal disorders | 0/21 | 3/20 | 6/10 | 3/21 |
| AnaemiaBlood and lymphatic system disorders | 1/21 | 1/20 | 3/10 | 11/21 |
| FatigueGeneral disorders | 5/21 | 1/20 | 3/10 | 1/21 |
| AstheniaGeneral disorders | 1/21 | 2/20 | 3/10 | 1/21 |
| NeutropeniaBlood and lymphatic system disorders | 0/21 | 2/20 | 3/10 | 0/21 |
| VomitingGastrointestinal disorders | 0/21 | 1/20 | 3/10 | 3/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/21 | 0/20 | 0/10 | 2/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/21 | 4/20 | 0/10 | 1/21 |
The Full Analysis Set (FAS) included all treated participants.
| Age, Customized(Participants) | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib | Total |
|---|---|---|---|---|---|
| < 50 | 2 | 0 | 1 | 2 | 5 |
| ≥ 50 to < 65 | 13 | 12 | 5 | 12 | 42 |
| ≥ 65 to < 75 | 6 | 6 | 3 | 5 | 20 |
| ≥ 75 to < 80 | 0 | 2 | 1 | 2 | 5 |
| ≥ 80 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib | Total |
|---|---|---|---|---|---|
| Female | 6 | 4 | 2 | 7 | 19 |
| Male | 15 | 16 | 8 | 14 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 21 | 19 | 10 | 21 | 71 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Arm A: Durvalumab + Tremelimumab (Original Cohort) | Arm A: Durvalumab + Tremelimumab (Expansion Cohort) | Arm B: Adavosertib + Carboplatin | Arm C: Ceralasertib (AZD6738) + Olaparib | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 21 | 20 | 10 | 21 | 72 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2016 to primary completion in Jun 2020, 42 months.
Results were first posted in Sep 2021, 1 year 2 months after primary completion.
Of 54 industry-sponsored phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 44. This study's 42 months is above that.
Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adavosertib · Carboplatin · Ceralasertib · Olaparib · Durvalumab · Tremelimumab